s Serratus Anterior Block for Perioperative Analgesia
Launched by ZAGAZIG UNIVERSITY · May 8, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new method called the serratus anterior block to help manage pain after a type of breast surgery known as modified radical mastectomy. The goal is to provide effective pain relief while reducing the need for opioids, which can have unwanted side effects. The trial aims to find out if this technique can offer a safer, easier, and more comfortable option for women undergoing this surgery.
To participate in the trial, women aged 21 to 60 who are scheduled for a unilateral modified radical mastectomy may be eligible, provided they have a healthy body weight and don’t have certain medical conditions or allergies. Participants will receive the new pain management technique during their surgery and will be monitored for how well it works and any side effects. This study is currently recruiting participants and seeks to improve postoperative pain management for future patients.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent from the patient.
- • Age: 21 - 60 years old.
- • Gender: female patients.
- • Body mass index: \< 35 kg/m2.
- • Physical status: ASA grade I-II (American society of anesthiologists).
- • Type of operation: unilateral modified radical mastectomy operation.
- Exclusion Criteria:
- • • Patient with known history of allergy to study drugs.
- • Chronic use of analgesics or drug dependence.
- • Patients not able to understand pain assessment test.
- • Anatomical abnormalities.
- • Neuropathic disease.
- • Pregnancy or breast feeding.
- • Other contraindication of regional anesthesia e.g. septic focus at site of injection.
- • patient with coagulopathy or on anticoagulant therapy.
About Zagazig University
Zagazig University, a prominent educational and research institution located in Egypt, plays a pivotal role in advancing medical knowledge and promoting health innovations through its clinical trials. With a commitment to excellence in research, the university leverages its diverse expertise and state-of-the-art facilities to conduct rigorous clinical studies that aim to improve patient care and outcomes. By fostering collaboration among multidisciplinary teams, Zagazig University contributes significantly to the global medical community, ensuring that its clinical trials adhere to the highest ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zagazig, Md, Egypt
Patients applied
Trial Officials
Halah I Zanfaly, MD
Principal Investigator
Zagazig University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported